F-box and leucine rich repeat protein 20Genealiases: Fbl2 · Fbl20
Q-omics provides the consensus-scored FBXL20 profile across patient tissues and cancer cell-line models. FBXL20 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, FBXL20 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, FBXL20 protein abundance shows 33,605 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight OV, HNSC, and LUAD as cancer lineages where FBXL20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL20 survival associations across molecular data types. FBXL20 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL20 RNA expression–survival associations across cancer types. High FBXL20 expression shows unfavorable associations in OV, KICH and HNSC, but favorable associations in KIRC, LUAD and READ. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for FBXL20 RNA expression.
This table summarizes FBXL20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for FBXL20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL20 shows higher tumor expression in HNSC, KIRP, LIHC, CHOL, KIRC and PRAD. The HNSC box plot shows higher FBXL20 RNA expression in tumor versus normal tissue (log2 FC = +0.556, t-test p < 0.001).
This table shows molecular features associated with FBXL20 in patient tissues and cancer cell lines. In patient samples, FBXL20 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
